L-DOPA-induced dyskinesia (LID) in Parkinson’s disease has been linked to oscillatory neuronal activities in the cortico-basal ganglia network. We set out to examine the pattern of cortico-basal ganglia oscillations induced by selective agonists of D1 and D2 receptors in a rat model of LID. Local field potentials were recorded in freely moving rats using large-scale electrodes targeting three motor cortical regions, dorsomedial and dorsolateral striatum, external globus pallidus, and substantial nigra pars reticulata. Abnormal involuntary movements were elicited by the D1 agonist SKF82958 or the D2 agonist sumanirole, while overall motor activity was quantified using video analysis (DeepLabCut). Both SKF82958 and sumanirole induced dyskines...
Introduction: The nigrostriatal dopamine (DA) containing neurones are a pivotal component in the bas...
Repeated treatment with dopamine (DA) receptor agonists strongly potentiates contralateral turning b...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...
L-DOPA-induced dyskinesia (LID) in Parkinson’s disease has been linked to oscillatory neuronal activ...
L-DOPA-induced dyskinesia (LID) is a significant complication of dopamine replacement therapy in Par...
The basal ganglia are thought to be particularly sensitive to changes in dopaminergic tone, and the ...
Excessive theta (theta) frequency oscillation and synchronization in the basal ganglia (BG) has been...
The standard pharmacological treatment for Parkinson's disease using the dopamine precursor levodopa...
With the advent of rodent models of l-DOPA-induced dyskinesia (LID), a growing literature has linked...
Recently, the biased and highly selective 5-HT1A agonists, NLX-112, F13714 and F15599, have been sho...
Evidence for an involvement of striatal D1 receptors in levodopa-induced dyskinesia has been present...
Parkinson's disease (PD) is a neurodegenerative disorder characterised by typicalmotor symptoms that...
Evidence for in vivo involvement of striatal D1 receptors in levodopa-induced dyskinesia has been pr...
The loss of dopamine (DA) in Parkinson's is accompanied by the emergence of exaggerated theta and be...
The loss of dopamine (DA) in Parkinson's is accompanied by the emergence of exaggerated theta and be...
Introduction: The nigrostriatal dopamine (DA) containing neurones are a pivotal component in the bas...
Repeated treatment with dopamine (DA) receptor agonists strongly potentiates contralateral turning b...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...
L-DOPA-induced dyskinesia (LID) in Parkinson’s disease has been linked to oscillatory neuronal activ...
L-DOPA-induced dyskinesia (LID) is a significant complication of dopamine replacement therapy in Par...
The basal ganglia are thought to be particularly sensitive to changes in dopaminergic tone, and the ...
Excessive theta (theta) frequency oscillation and synchronization in the basal ganglia (BG) has been...
The standard pharmacological treatment for Parkinson's disease using the dopamine precursor levodopa...
With the advent of rodent models of l-DOPA-induced dyskinesia (LID), a growing literature has linked...
Recently, the biased and highly selective 5-HT1A agonists, NLX-112, F13714 and F15599, have been sho...
Evidence for an involvement of striatal D1 receptors in levodopa-induced dyskinesia has been present...
Parkinson's disease (PD) is a neurodegenerative disorder characterised by typicalmotor symptoms that...
Evidence for in vivo involvement of striatal D1 receptors in levodopa-induced dyskinesia has been pr...
The loss of dopamine (DA) in Parkinson's is accompanied by the emergence of exaggerated theta and be...
The loss of dopamine (DA) in Parkinson's is accompanied by the emergence of exaggerated theta and be...
Introduction: The nigrostriatal dopamine (DA) containing neurones are a pivotal component in the bas...
Repeated treatment with dopamine (DA) receptor agonists strongly potentiates contralateral turning b...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...